Profile - To The Moon

Likelike

Like like

Posts · 45Posts · 45
Following · 0Following · 0
Followers · 0Followers · 0

- LikelikeLikelike
  ·2024-10-28
  $Apple(AAPL)$
  88 1
  Like
  Share
  Report
- LikelikeLikelike
  ·2024-10-21
  $Apple(AAPL)$
  195 Comment
  Like
  Share
  Report
- LikelikeLikelike
  ·2023-02-02
  thanks 😊
  323 Comment
  Like
  Share
  Report
- LikelikeLikelike
  ·2021-09-23
  Nio niu (bull)ah!
  Nio Said To Delay Unveiling Of ES8, Nio House In Norway By A Week
  Chinese electric vehicle maker NIO Inc. is delaying the official launch of the ES8 SUV and the openi
  Nio Said To Delay Unveiling Of ES8, Nio House In Norway By A Week
  706 1
  6
  Share
  Report
- LikelikeLikelike
  ·2021-09-23
  Pfizer can reach $50 by Oct....i wish
  Despite Vaccine Uncertainty, Pfizer Is a Buy
  Forget the booster shot controversy, PFE stock has better days ahead. What would happen if a compan
  Despite Vaccine Uncertainty, Pfizer Is a Buy
  497 3
  5
  Share
  Report
- LikelikeLikelike
  ·2021-09-22
  Maybe Apple can consider learn from Xiaomi,sell Smart systems on almost everything from robot vaccum to humidifier haha....
  Apple sees 5M iPhone 13 pre-orders in China--report
  Barely $one$ week after unveiling the iPhone 13, $Apple$ is already seeing strong initial demand for its flagship product coming out of China.TheSouth China Morning $Post$reported Wednesday that approximately 5 million pre-orders of the iPhone 13 have been made in the eight days since Apple Chief Executive Tim Cook showed of the smartphone. ThePostsaid that online traffic was so heavy that Apple's China site slowed to a crawl, and that Chinese e-commerce company $JD.com$took more than 3 million
  Apple sees 5M iPhone 13 pre-orders in China--report
  525 3
  5
  Share
  Report
- LikelikeLikelike
  ·2021-09-14
  ford should be a $15 share..i wish
  Sorry, this post has been deleted
  578 4
  4
  Share
  Report
- LikelikeLikelike
  ·2021-09-14
  sold first maybe buy later <8,pls like n share your comments thanks
  Ocugen shares surged more than 13% in Monday morning trading
  Ocugen shares surged more than 13% in Monday morning trading. Various companies have been engaged i
  Ocugen shares surged more than 13% in Monday morning trading
  463 1
  4
  Share
  Report
- LikelikeLikelike
  ·2021-09-12
  $19X by end year
  Sorry, this post has been deleted
  433 Comment
  1
  Share
  Report
- LikelikeLikelike
  ·2021-09-04
  $NIO Inc.(NIO)$hope to reach half Tesla price haha
  760 1
  6
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"4091708143350050","uuid":"4091708143350050","gmtCreate":1628605862019,"gmtModify":1632926032280,"name":"Likelike","pinyin":"likelike","introduction":"","introductionEn":null,"signature":"Like like","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":29,"headSize":104,"tweetSize":45,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.84%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"60.14%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":9,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":364998089552032,"gmtCreate":1730121102013,"gmtModify":1730121106849,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$ </a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$ </a>&nbsp;","text":"$Apple(AAPL)$","images":[{"img":"https://community-static.tradeup.com/news/97f1fb631fa117474fa95250eb4e31cd","width":"870","height":"1772"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/364998089552032","isVote":1,"tweetType":1,"viewCount":88,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"10000000000010968","authorId":"10000000000010968","name":"Tiger_CashBoostAccount","avatar":"https://community-static.tradeup.com/news/ae2d4002ef9664aba005cb3020f416f5","crmLevel":1,"crmLevelSwitch":0,"idStr":"10000000000010968","authorIdStr":"10000000000010968"},"content":"Great job on your latest stock market success! Your commitment to research and analysis is evident in your results. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🥳💹💰🤩 Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.","text":"Great job on your latest stock market success! Your commitment to research and analysis is evident in your results. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🥳💹💰🤩 Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.","html":"Great job on your latest stock market success! Your commitment to research and analysis is evident in your results. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🥳💹💰🤩 Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":362453877051392,"gmtCreate":1729525626876,"gmtModify":1729525631290,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$ </a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$ </a>&nbsp;","text":"$Apple(AAPL)$","images":[{"img":"https://community-static.tradeup.com/news/f3b0375635ab832502e55203cfa6ae4b","width":"1080","height":"2379"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/362453877051392","isVote":1,"tweetType":1,"viewCount":195,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9955145856,"gmtCreate":1675301485576,"gmtModify":1676538990786,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;thanks&nbsp;😊&nbsp;","listText":"&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;thanks&nbsp;😊&nbsp;","text":"thanks 😊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9955145856","isVote":1,"tweetType":1,"viewCount":323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":863228838,"gmtCreate":1632400543624,"gmtModify":1676530772779,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Nio niu (bull)ah!","listText":"Nio niu (bull)ah!","text":"Nio niu (bull)ah!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/863228838","repostId":"1135139549","repostType":4,"repost":{"id":"1135139549","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1632386313,"share":"https://ttm.financial/m/news/1135139549?lang=&edition=fundamental","pubTime":"2021-09-23 16:38","market":"us","language":"en","title":"Nio Said To Delay Unveiling Of ES8, Nio House In Norway By A Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1135139549","media":"Benzinga","summary":"Chinese electric vehicle maker NIO Inc. is delaying the official launch of the ES8 SUV and the openi","content":"<p>Chinese electric vehicle maker&nbsp;<b><a href=\"https://laohu8.com/S/NIO\">NIO Inc.</a></b> is delaying the official launch of the ES8 SUV and the opening of the first overseas&nbsp;<b>Nio House</b>&nbsp;in Norway by a week, cnEVpostreportedWednesday.</p>\n<p><b>What Happened</b>: Nio will now launch the ES8 in Norway on Sept. 30 while the first local Nio House in Oslo will be officially open for business from Oct. 1, as per the report that&nbsp;<b>Marius Hayler</b>, general manager of Nio Norway.</p>\n<p>The report did not provide any details about the reasons for the delay. It was&nbsp;reported&nbsp;earlier this month the EV maker will open the Nio House in Norway and also announce the local pricing of its flagship ES8 model on Sept. 23.</p>\n<p>Nio House is the EV maker’s concept store.</p>\n<p><b>Why It Matters</b>: &nbsp;Nio’s entry into Norway marks the first step in an ambitious overseas expansion plan charted by the EV maker, which has found success in <a href=\"https://laohu8.com/S/CAAS\">China</a> as a seller of premium electric vehicles.</p>\n<p>NIO CEO<b>Wiliam Li</b>has said that the company may expand into Germany, followed by other European countries, if it achieves success in Norway.</p>\n<p><b>Price Action</b>: Nio shares closed almost 2.3% higher in Wednesday’s trading at $35.70.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio Said To Delay Unveiling Of ES8, Nio House In Norway By A Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio Said To Delay Unveiling Of ES8, Nio House In Norway By A Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-09-23 16:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Chinese electric vehicle maker&nbsp;<b><a href=\"https://laohu8.com/S/NIO\">NIO Inc.</a></b> is delaying the official launch of the ES8 SUV and the opening of the first overseas&nbsp;<b>Nio House</b>&nbsp;in Norway by a week, cnEVpostreportedWednesday.</p>\n<p><b>What Happened</b>: Nio will now launch the ES8 in Norway on Sept. 30 while the first local Nio House in Oslo will be officially open for business from Oct. 1, as per the report that&nbsp;<b>Marius Hayler</b>, general manager of Nio Norway.</p>\n<p>The report did not provide any details about the reasons for the delay. It was&nbsp;reported&nbsp;earlier this month the EV maker will open the Nio House in Norway and also announce the local pricing of its flagship ES8 model on Sept. 23.</p>\n<p>Nio House is the EV maker’s concept store.</p>\n<p><b>Why It Matters</b>: &nbsp;Nio’s entry into Norway marks the first step in an ambitious overseas expansion plan charted by the EV maker, which has found success in <a href=\"https://laohu8.com/S/CAAS\">China</a> as a seller of premium electric vehicles.</p>\n<p>NIO CEO<b>Wiliam Li</b>has said that the company may expand into Germany, followed by other European countries, if it achieves success in Norway.</p>\n<p><b>Price Action</b>: Nio shares closed almost 2.3% higher in Wednesday’s trading at $35.70.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135139549","content_text":"Chinese electric vehicle maker NIO Inc. is delaying the official launch of the ES8 SUV and the opening of the first overseas Nio House in Norway by a week, cnEVpostreportedWednesday.\nWhat Happened: Nio will now launch the ES8 in Norway on Sept. 30 while the first local Nio House in Oslo will be officially open for business from Oct. 1, as per the report that Marius Hayler, general manager of Nio Norway.\nThe report did not provide any details about the reasons for the delay. It was reported earlier this month the EV maker will open the Nio House in Norway and also announce the local pricing of its flagship ES8 model on Sept. 23.\nNio House is the EV maker’s concept store.\nWhy It Matters:  Nio’s entry into Norway marks the first step in an ambitious overseas expansion plan charted by the EV maker, which has found success in China as a seller of premium electric vehicles.\nNIO CEOWiliam Lihas said that the company may expand into Germany, followed by other European countries, if it achieves success in Norway.\nPrice Action: Nio shares closed almost 2.3% higher in Wednesday’s trading at $35.70.","news_type":1},"isVote":1,"tweetType":1,"viewCount":706,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":863229400,"gmtCreate":1632400374400,"gmtModify":1676530772716,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Pfizer can reach $50 by Oct....i wish","listText":"Pfizer can reach $50 by Oct....i wish","text":"Pfizer can reach $50 by Oct....i wish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/863229400","repostId":"1133566174","repostType":4,"repost":{"id":"1133566174","kind":"news","pubTimestamp":1632397453,"share":"https://ttm.financial/m/news/1133566174?lang=&edition=fundamental","pubTime":"2021-09-23 19:44","market":"us","language":"en","title":"Despite Vaccine Uncertainty, Pfizer Is a Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=1133566174","media":"InvestorPlace","summary":"Forget the booster shot controversy, PFE stock has better days ahead.\n\nWhat would happen if a compan","content":"<blockquote>\n <b>Forget the booster shot controversy, PFE stock has better days ahead.</b>\n</blockquote>\n<p>What would happen if a company developed a massive new product and no <a href=\"https://laohu8.com/S/AONE.U\">one</a> cared? For&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>’s</b> investors, that has been the question for the past year. Despite coming up with a blockbuster vaccine for the novel coronavirus, PFE stock did basically nothing for an extended period.</p>\n<p>That finally changed this summer, when Pfizer belatedly rallied to new all-time highs. Now though, the gains are fading almost as quickly as they happened. In its <a href=\"https://laohu8.com/S/QTWO\">Q2</a> earnings release, Pfizer reported 93% year-over-year revenue growth. Yet shares are up less than 20% over the past 12 months. Why have investors not given Pfizer credit for its performance, and will that change in the future?</p>\n<p><b>Vaccine Hits A Setback</b></p>\n<p>Pfizer has enjoyed incredible revenue growth over the past year due to its Covid-19 vaccine. The majority of vaccinated <a href=\"https://laohu8.com/S/AFG\">American</a> adults have taken the Pfizer vaccine, and it’s had strong sales overseas as well.</p>\n<p>Despite that, however, PFE stock didn’t move too much. At least, not until July of this year. At that time, PFE stock finally took off. The reason why is that investors started to price in the expectation that people would need to take vaccine booster shots to maintain efficacy.</p>\n<p>The idea of a third, and potentially even fourth or more dose of vaccines would have created a far more enduring revenue boost for Pfizer. Up until recently, investors had shied away from Pfizer despite its massive top-line growth because they anticipated that the Covid business would quickly recede. With booster shots, however, the vaccine would have taken on another level of importance to the company.</p>\n<p>This scenario is now under increasing doubt, however. A Food and Drug Administration (FDA) advisory panel recentlyrecommended againstadvising booster shots of the Pfizer vaccine. A large majority of the panelists voted that the data on hand was insufficient to warrant booster shots. That comes amid reports that&nbsp;<b>Moderna’s</b>(NASDAQ:<b><u>MRNA</u></b>) vaccine remains effective in a higher percentage of people than Pfizer’s after 120 days.</p>\n<p>This is hardly the final word on booster shots or the efficacy of Moderna versus Pfizer. Pfizer’s investors shouldn’t discount the possibility that the FDA later comes around on additional rounds of the vaccine. For now, however, the prospects are looking more uncertain.</p>\n<p><b>Baseline Valuation Is Not That Demanding</b></p>\n<p>Let’s go back in time to 2019 and pretend that we’ve never heard of the pandemic. What does an investment in Pfizer look like in this hypothetical scenario? For full-year 2018, Pfizer generated $1.87 of EPS. In 2019, this leapt to $2.87.</p>\n<p>Based on today’s stock price just below $44, PFE stock is selling at 23x 2018 earnings or 15x 2019 earnings. With no benefit from the current Covid-19 vaccine whatsoever, Pfizer stock would still be going for a reasonable multiple.</p>\n<p>Yes, you can argue that pharmaceutical companies should trade for lower P/E multiples than many other industries given the high cost of drug development and quick patent expiries. Still, with earnings as strong as they were in 2018-19, it’s not hard to get behind the stock at $44 even if you give the company zero credit for the Covid-19 vaccine. Forget about booster shots for a minute, traders are pricing Pfizer like there will be little more revenue from the vaccine whatsoever.</p>\n<p><b>PFE Stock Verdict</b></p>\n<p>Right now, Pfizer stock is inextricably linked to its vaccine’s outlook. When there is positive news on that front, PFE stock surges. When there is a setback, PFE stock sells off hard. That’s a totally understandable market reaction. Many traders are trained to react quickly to the latest headline.</p>\n<p>For longer-term investors, however, Pfizer is an opportunity regardless of the trajectory of the vaccine. Even if boosters ultimately aren’t a big thing, Pfizer can still make investors money from this entry point.</p>\n<p>The company is a tremendous diversified pharmaceutical giant. It was in good shape long before the pandemic, and it has dozens of promising drugs in its pipeline to power it for the next decade and beyond. The company is reaping a windfall right now, but it’s not like that’s its only iron in the fire.</p>\n<p>If the Covid-19 business continues longer than forecast, that’s all upside to the stock price. However, from this starting point, there’s sufficient margin of safety to support a purchase in most possible outcomes.</p>\n<p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Despite Vaccine Uncertainty, Pfizer Is a Buy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDespite Vaccine Uncertainty, Pfizer Is a Buy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-23 19:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/09/despite-vaccine-uncertainty-pfizer-is-a-buy/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forget the booster shot controversy, PFE stock has better days ahead.\n\nWhat would happen if a company developed a massive new product and no one cared? For Pfizer’s investors, that has been the ...</p>\n\n<a href=\"https://investorplace.com/2021/09/despite-vaccine-uncertainty-pfizer-is-a-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://investorplace.com/2021/09/despite-vaccine-uncertainty-pfizer-is-a-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133566174","content_text":"Forget the booster shot controversy, PFE stock has better days ahead.\n\nWhat would happen if a company developed a massive new product and no one cared? For Pfizer’s investors, that has been the question for the past year. Despite coming up with a blockbuster vaccine for the novel coronavirus, PFE stock did basically nothing for an extended period.\nThat finally changed this summer, when Pfizer belatedly rallied to new all-time highs. Now though, the gains are fading almost as quickly as they happened. In its Q2 earnings release, Pfizer reported 93% year-over-year revenue growth. Yet shares are up less than 20% over the past 12 months. Why have investors not given Pfizer credit for its performance, and will that change in the future?\nVaccine Hits A Setback\nPfizer has enjoyed incredible revenue growth over the past year due to its Covid-19 vaccine. The majority of vaccinated American adults have taken the Pfizer vaccine, and it’s had strong sales overseas as well.\nDespite that, however, PFE stock didn’t move too much. At least, not until July of this year. At that time, PFE stock finally took off. The reason why is that investors started to price in the expectation that people would need to take vaccine booster shots to maintain efficacy.\nThe idea of a third, and potentially even fourth or more dose of vaccines would have created a far more enduring revenue boost for Pfizer. Up until recently, investors had shied away from Pfizer despite its massive top-line growth because they anticipated that the Covid business would quickly recede. With booster shots, however, the vaccine would have taken on another level of importance to the company.\nThis scenario is now under increasing doubt, however. A Food and Drug Administration (FDA) advisory panel recentlyrecommended againstadvising booster shots of the Pfizer vaccine. A large majority of the panelists voted that the data on hand was insufficient to warrant booster shots. That comes amid reports that Moderna’s(NASDAQ:MRNA) vaccine remains effective in a higher percentage of people than Pfizer’s after 120 days.\nThis is hardly the final word on booster shots or the efficacy of Moderna versus Pfizer. Pfizer’s investors shouldn’t discount the possibility that the FDA later comes around on additional rounds of the vaccine. For now, however, the prospects are looking more uncertain.\nBaseline Valuation Is Not That Demanding\nLet’s go back in time to 2019 and pretend that we’ve never heard of the pandemic. What does an investment in Pfizer look like in this hypothetical scenario? For full-year 2018, Pfizer generated $1.87 of EPS. In 2019, this leapt to $2.87.\nBased on today’s stock price just below $44, PFE stock is selling at 23x 2018 earnings or 15x 2019 earnings. With no benefit from the current Covid-19 vaccine whatsoever, Pfizer stock would still be going for a reasonable multiple.\nYes, you can argue that pharmaceutical companies should trade for lower P/E multiples than many other industries given the high cost of drug development and quick patent expiries. Still, with earnings as strong as they were in 2018-19, it’s not hard to get behind the stock at $44 even if you give the company zero credit for the Covid-19 vaccine. Forget about booster shots for a minute, traders are pricing Pfizer like there will be little more revenue from the vaccine whatsoever.\nPFE Stock Verdict\nRight now, Pfizer stock is inextricably linked to its vaccine’s outlook. When there is positive news on that front, PFE stock surges. When there is a setback, PFE stock sells off hard. That’s a totally understandable market reaction. Many traders are trained to react quickly to the latest headline.\nFor longer-term investors, however, Pfizer is an opportunity regardless of the trajectory of the vaccine. Even if boosters ultimately aren’t a big thing, Pfizer can still make investors money from this entry point.\nThe company is a tremendous diversified pharmaceutical giant. It was in good shape long before the pandemic, and it has dozens of promising drugs in its pipeline to power it for the next decade and beyond. The company is reaping a windfall right now, but it’s not like that’s its only iron in the fire.\nIf the Covid-19 business continues longer than forecast, that’s all upside to the stock price. However, from this starting point, there’s sufficient margin of safety to support a purchase in most possible outcomes.","news_type":1},"isVote":1,"tweetType":1,"viewCount":497,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4092216435500580","authorId":"4092216435500580","name":"SimonSim","avatar":"https://static.tigerbbs.com/f2870d5ab54ba75f2d74ad8cb044473a","crmLevel":2,"crmLevelSwitch":0,"idStr":"4092216435500580","authorIdStr":"4092216435500580"},"content":"[Happy] [Happy] [Happy]","text":"[Happy] [Happy] [Happy]","html":"[Happy] [Happy] [Happy]"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869784588,"gmtCreate":1632322282944,"gmtModify":1676530752993,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"Maybe&nbsp;Apple can consider learn from Xiaomi,sell Smart systems on almost everything from robot vaccum to humidifier haha....","listText":"Maybe&nbsp;Apple can consider learn from Xiaomi,sell Smart systems on almost everything from robot vaccum to humidifier haha....","text":"Maybe Apple can consider learn from Xiaomi,sell Smart systems on almost everything from robot vaccum to humidifier haha....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/869784588","repostId":"1143821004","repostType":4,"repost":{"id":"1143821004","kind":"news","pubTimestamp":1632320072,"share":"https://ttm.financial/m/news/1143821004?lang=&edition=fundamental","pubTime":"2021-09-22 22:14","market":"us","language":"en","title":"Apple sees 5M iPhone 13 pre-orders in China--report","url":"https://stock-news.laohu8.com/highlight/detail?id=1143821004","media":"seekingalpha","summary":"Barely $one$ week after unveiling the iPhone 13, $Apple$ is already seeing strong initial demand for its flagship product coming out of China.TheSouth China Morning $Post$reported Wednesday that approximately 5 million pre-orders of the iPhone 13 have been made in the eight days since Apple  Chief Executive Tim Cook showed of the smartphone. ThePostsaid that online traffic was so heavy that Apple's China site slowed to a crawl, and that Chinese e-commerce company $JD.com$took more than 3 million","content":"<p>Barely <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after unveiling the iPhone 13, <a href=\"https://laohu8.com/S/AAPL\">Apple</a>&nbsp;is already seeing strong initial demand for its flagship product coming out of China.</p>\n<p>The<i>South China Morning <a href=\"https://laohu8.com/S/POST\">Post</a></i>reported Wednesday that approximately 5 million pre-orders of the iPhone 13 have been made in the eight days since Apple (AAPL) Chief Executive Tim Cook showed of the smartphone. The<i>Post</i>said that online traffic was so heavy that Apple's China site slowed to a crawl, and that Chinese e-commerce company <a href=\"https://laohu8.com/S/JD\">JD.com</a>(NASDAQ:JD)took more than 3 million iPhone 13 pre-order</p>\n<p>The four new iPhones--iPhone 13, iPhone 13 Mini, iPhone 13 Pro and iPhone 13 Pro Max--officially go on sale on September 24.</p>\n<p>Earlier this week, <a href=\"https://laohu8.com/S/BAC\">Bank of America</a> analyst Wamsi Mohan said in a research report that initial retail checks showediPhone 13 pre-orders outpacing those of the iPhone 12 a year ago.</p>\n<p>Apple gained over 1% in early trading.</p>\n<p><img src=\"https://static.tigerbbs.com/ac2063b03f2196c3d0a449ab604bd718\" tg-width=\"972\" tg-height=\"561\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple sees 5M iPhone 13 pre-orders in China--report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple sees 5M iPhone 13 pre-orders in China--report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-22 22:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3742266-apple-sees-5m-iphone-pre-orders-in-china-report><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Barely one week after unveiling the iPhone 13, Apple is already seeing strong initial demand for its flagship product coming out of China.\nTheSouth China Morning Postreported Wednesday that ...</p>\n\n<a href=\"https://seekingalpha.com/news/3742266-apple-sees-5m-iphone-pre-orders-in-china-report\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://seekingalpha.com/news/3742266-apple-sees-5m-iphone-pre-orders-in-china-report","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1143821004","content_text":"Barely one week after unveiling the iPhone 13, Apple is already seeing strong initial demand for its flagship product coming out of China.\nTheSouth China Morning Postreported Wednesday that approximately 5 million pre-orders of the iPhone 13 have been made in the eight days since Apple (AAPL) Chief Executive Tim Cook showed of the smartphone. ThePostsaid that online traffic was so heavy that Apple's China site slowed to a crawl, and that Chinese e-commerce company JD.com(NASDAQ:JD)took more than 3 million iPhone 13 pre-order\nThe four new iPhones--iPhone 13, iPhone 13 Mini, iPhone 13 Pro and iPhone 13 Pro Max--officially go on sale on September 24.\nEarlier this week, Bank of America analyst Wamsi Mohan said in a research report that initial retail checks showediPhone 13 pre-orders outpacing those of the iPhone 12 a year ago.\nApple gained over 1% in early trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":525,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3580536610076415","authorId":"3580536610076415","name":"BettyT","avatar":"https://static.tigerbbs.com/6a4dfe2f455acd2af7629f83ce30e20c","crmLevel":4,"crmLevelSwitch":0,"idStr":"3580536610076415","authorIdStr":"3580536610076415"},"content":"diversified ? Haha ??","text":"diversified ? Haha ??","html":"diversified ? Haha ??"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886336965,"gmtCreate":1631549461457,"gmtModify":1676530574165,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"ford should be a $15 share..i wish","listText":"ford should be a $15 share..i wish","text":"ford should be a $15 share..i wish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/886336965","repostId":"2167658404","repostType":2,"isVote":1,"tweetType":1,"viewCount":578,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3586655655659820","authorId":"3586655655659820","name":"sunshine138","avatar":"https://static.tigerbbs.com/23149c63a63bfeec1572cc27e1322750","crmLevel":3,"crmLevelSwitch":0,"idStr":"3586655655659820","authorIdStr":"3586655655659820"},"content":"When will it move there","text":"When will it move there","html":"When will it move there"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886333560,"gmtCreate":1631549154550,"gmtModify":1676530574110,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"sold first maybe buy later &lt;8,pls like n share your comments&nbsp;thanks","listText":"sold first maybe buy later &lt;8,pls like n share your comments&nbsp;thanks","text":"sold first maybe buy later <8,pls like n share your comments thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/886333560","repostId":"1126978010","repostType":4,"repost":{"id":"1126978010","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631544701,"share":"https://ttm.financial/m/news/1126978010?lang=&edition=fundamental","pubTime":"2021-09-13 22:51","market":"us","language":"en","title":"Ocugen shares surged more than 13% in Monday morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126978010","media":"Tiger Newspress","summary":"Ocugen shares surged more than 13% in Monday morning trading.\n\nVarious companies have been engaged i","content":"<p>Ocugen shares surged more than 13%&nbsp;in Monday morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/8fcba6c91ee88af0dd90608a79065282\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>Various companies have been engaged in producing COVID-19 vaccines since the onset of the pandemic.</p>\n<p>Clinical-stage biotech firm Ocugen (<b>OCGN</b>) joined the race in December 2020, announcing its partnership with India-based Bharat Biotech. Ocugen collaborated with the Indian biotech company to jointly develop Covaxin.</p>\n<p>The announcement helped its stock to propel from under 30 cents a share to a stunning, eventual high of&nbsp;$18.77 a share in February. However, prices plummeted to nearly $9 per share in the next month.</p>\n<p>As rival companies came forward with their vaccines while Ocugen lagged behind, the stock started to bleed.</p>\n<p>However, OCGN stock is once again witnessing an upward move. Here’s a detailed analysis to find out what’s really happening with the stock. I’m neutral on Ocugen.</p>\n<p><b>Delta Variant Concerns Pushing OCGN Stock up</b></p>\n<p>Newly discovered variants of COVID-19 have been a major cause of concern lately. These variants are more infectious, and resistant, to the already existing COVID-19 vaccines. The Delta variant is one such dangerous strain that has caught the attention of people worldwide.</p>\n<p>This new variant has piqued global interest in Ocugen, and its Covaxin. Notably, Covaxin is yet to receive approval from FDA. However, the once-forgotten OCGN stock is again back in the discussion, with stock prices moving up by a decent 8.5% in August.</p>\n<p>According to many analysts, value investors aren’t interested in this stock. Rather, it is mainly retail investors who are eyeing Ocugen for some quick profit.</p>\n<p><b>Short-term Catalyst behind the Sudden Spike</b></p>\n<p>Ocugen has been jointly developing Covaxin with Bharat Biotech for use in the North American market. Share prices suffered a decline when Ocugen was denied emergency-use authorization from the FDA, which recommended that the company apply for a biologics-license application instead.</p>\n<p>Health Canada is reviewing Covaxin currently. It has not yet been granted approval. However, the news of review was enough to push Ocugen stock higher.</p>\n<p>Moreover, the company intends to submit an Investigational New Drug application for one of its gene therapy candidates. OCU400 is designed to target retinal diseases. Ocugen has already started to assess options to begin trials in Europe in 2022.</p>\n<p><b>Ocugen Needs to Progress</b></p>\n<p>The biotech company released a much-awaited business update on August 6. Ocugen failed to generate revenue during the second quarter. Unlike many of its rivals, it doesn’t have any commercialized products at the moment.</p>\n<p>On top of that, it posted a&nbsp;net loss of $26 million during Q2. Expenses related to research and development stood at $18.9 million in the current quarter, as opposed to $1.6 million last year. In addition, administrative expenses increased by 279.8% year-over-year, to $6.8 million.</p>\n<p>As of June 30, cash and cash equivalents stood at $115.6 million.</p>\n<p><b>Wall Street’s Take</b></p>\n<p>As per TipRanks’ analyst rating consensus, Ocugen stock is a Moderate Buy. Out of four analysts, there are two Buy recommendations, and two Hold recommendations.</p>\n<p>The&nbsp;average OCGN price target&nbsp;is $8.88. The analyst price targets range from a high of $15 per share, to a low of $4.50 per share.</p>\n<p><img src=\"https://static.tigerbbs.com/9c696ea686fdeaa8d6550e1282efebf7\" tg-width=\"1099\" tg-height=\"374\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Bottom Line</b></p>\n<p>Ocugen stock could very well profit from the mounting global concerns about the Delta variant.</p>\n<p>There might even be a stock rally. However, the company is badly in need of positive regulatory updates right now.</p>\n<p>It’s an interesting play, but not without risk.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen shares surged more than 13% in Monday morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen shares surged more than 13% in Monday morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-13 22:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ocugen shares surged more than 13%&nbsp;in Monday morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/8fcba6c91ee88af0dd90608a79065282\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>Various companies have been engaged in producing COVID-19 vaccines since the onset of the pandemic.</p>\n<p>Clinical-stage biotech firm Ocugen (<b>OCGN</b>) joined the race in December 2020, announcing its partnership with India-based Bharat Biotech. Ocugen collaborated with the Indian biotech company to jointly develop Covaxin.</p>\n<p>The announcement helped its stock to propel from under 30 cents a share to a stunning, eventual high of&nbsp;$18.77 a share in February. However, prices plummeted to nearly $9 per share in the next month.</p>\n<p>As rival companies came forward with their vaccines while Ocugen lagged behind, the stock started to bleed.</p>\n<p>However, OCGN stock is once again witnessing an upward move. Here’s a detailed analysis to find out what’s really happening with the stock. I’m neutral on Ocugen.</p>\n<p><b>Delta Variant Concerns Pushing OCGN Stock up</b></p>\n<p>Newly discovered variants of COVID-19 have been a major cause of concern lately. These variants are more infectious, and resistant, to the already existing COVID-19 vaccines. The Delta variant is one such dangerous strain that has caught the attention of people worldwide.</p>\n<p>This new variant has piqued global interest in Ocugen, and its Covaxin. Notably, Covaxin is yet to receive approval from FDA. However, the once-forgotten OCGN stock is again back in the discussion, with stock prices moving up by a decent 8.5% in August.</p>\n<p>According to many analysts, value investors aren’t interested in this stock. Rather, it is mainly retail investors who are eyeing Ocugen for some quick profit.</p>\n<p><b>Short-term Catalyst behind the Sudden Spike</b></p>\n<p>Ocugen has been jointly developing Covaxin with Bharat Biotech for use in the North American market. Share prices suffered a decline when Ocugen was denied emergency-use authorization from the FDA, which recommended that the company apply for a biologics-license application instead.</p>\n<p>Health Canada is reviewing Covaxin currently. It has not yet been granted approval. However, the news of review was enough to push Ocugen stock higher.</p>\n<p>Moreover, the company intends to submit an Investigational New Drug application for one of its gene therapy candidates. OCU400 is designed to target retinal diseases. Ocugen has already started to assess options to begin trials in Europe in 2022.</p>\n<p><b>Ocugen Needs to Progress</b></p>\n<p>The biotech company released a much-awaited business update on August 6. Ocugen failed to generate revenue during the second quarter. Unlike many of its rivals, it doesn’t have any commercialized products at the moment.</p>\n<p>On top of that, it posted a&nbsp;net loss of $26 million during Q2. Expenses related to research and development stood at $18.9 million in the current quarter, as opposed to $1.6 million last year. In addition, administrative expenses increased by 279.8% year-over-year, to $6.8 million.</p>\n<p>As of June 30, cash and cash equivalents stood at $115.6 million.</p>\n<p><b>Wall Street’s Take</b></p>\n<p>As per TipRanks’ analyst rating consensus, Ocugen stock is a Moderate Buy. Out of four analysts, there are two Buy recommendations, and two Hold recommendations.</p>\n<p>The&nbsp;average OCGN price target&nbsp;is $8.88. The analyst price targets range from a high of $15 per share, to a low of $4.50 per share.</p>\n<p><img src=\"https://static.tigerbbs.com/9c696ea686fdeaa8d6550e1282efebf7\" tg-width=\"1099\" tg-height=\"374\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Bottom Line</b></p>\n<p>Ocugen stock could very well profit from the mounting global concerns about the Delta variant.</p>\n<p>There might even be a stock rally. However, the company is badly in need of positive regulatory updates right now.</p>\n<p>It’s an interesting play, but not without risk.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126978010","content_text":"Ocugen shares surged more than 13% in Monday morning trading.\n\nVarious companies have been engaged in producing COVID-19 vaccines since the onset of the pandemic.\nClinical-stage biotech firm Ocugen (OCGN) joined the race in December 2020, announcing its partnership with India-based Bharat Biotech. Ocugen collaborated with the Indian biotech company to jointly develop Covaxin.\nThe announcement helped its stock to propel from under 30 cents a share to a stunning, eventual high of $18.77 a share in February. However, prices plummeted to nearly $9 per share in the next month.\nAs rival companies came forward with their vaccines while Ocugen lagged behind, the stock started to bleed.\nHowever, OCGN stock is once again witnessing an upward move. Here’s a detailed analysis to find out what’s really happening with the stock. I’m neutral on Ocugen.\nDelta Variant Concerns Pushing OCGN Stock up\nNewly discovered variants of COVID-19 have been a major cause of concern lately. These variants are more infectious, and resistant, to the already existing COVID-19 vaccines. The Delta variant is one such dangerous strain that has caught the attention of people worldwide.\nThis new variant has piqued global interest in Ocugen, and its Covaxin. Notably, Covaxin is yet to receive approval from FDA. However, the once-forgotten OCGN stock is again back in the discussion, with stock prices moving up by a decent 8.5% in August.\nAccording to many analysts, value investors aren’t interested in this stock. Rather, it is mainly retail investors who are eyeing Ocugen for some quick profit.\nShort-term Catalyst behind the Sudden Spike\nOcugen has been jointly developing Covaxin with Bharat Biotech for use in the North American market. Share prices suffered a decline when Ocugen was denied emergency-use authorization from the FDA, which recommended that the company apply for a biologics-license application instead.\nHealth Canada is reviewing Covaxin currently. It has not yet been granted approval. However, the news of review was enough to push Ocugen stock higher.\nMoreover, the company intends to submit an Investigational New Drug application for one of its gene therapy candidates. OCU400 is designed to target retinal diseases. Ocugen has already started to assess options to begin trials in Europe in 2022.\nOcugen Needs to Progress\nThe biotech company released a much-awaited business update on August 6. Ocugen failed to generate revenue during the second quarter. Unlike many of its rivals, it doesn’t have any commercialized products at the moment.\nOn top of that, it posted a net loss of $26 million during Q2. Expenses related to research and development stood at $18.9 million in the current quarter, as opposed to $1.6 million last year. In addition, administrative expenses increased by 279.8% year-over-year, to $6.8 million.\nAs of June 30, cash and cash equivalents stood at $115.6 million.\nWall Street’s Take\nAs per TipRanks’ analyst rating consensus, Ocugen stock is a Moderate Buy. Out of four analysts, there are two Buy recommendations, and two Hold recommendations.\nThe average OCGN price target is $8.88. The analyst price targets range from a high of $15 per share, to a low of $4.50 per share.\n\nBottom Line\nOcugen stock could very well profit from the mounting global concerns about the Delta variant.\nThere might even be a stock rally. However, the company is badly in need of positive regulatory updates right now.\nIt’s an interesting play, but not without risk.","news_type":1},"isVote":1,"tweetType":1,"viewCount":463,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":888392488,"gmtCreate":1631431444744,"gmtModify":1676530547708,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"$19X&nbsp;by end year","listText":"$19X&nbsp;by end year","text":"$19X by end year","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/888392488","repostId":"2166904370","repostType":4,"isVote":1,"tweetType":1,"viewCount":433,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814358162,"gmtCreate":1630768928456,"gmtModify":1676530392740,"author":{"id":"4091708143350050","authorId":"4091708143350050","name":"Likelike","avatar":"https://static.tigerbbs.com/0c535dfd23243cbd1cba5aae16cf970c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4091708143350050","authorIdStr":"4091708143350050"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>hope to reach half Tesla price haha","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>hope to reach half Tesla price haha","text":"$NIO Inc.(NIO)$hope to reach half Tesla price haha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/814358162","isVote":1,"tweetType":1,"viewCount":760,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","crmLevel":6,"crmLevelSwitch":1,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"content":"Nio to the moon??????","text":"Nio to the moon??????","html":"Nio to the moon??????"}],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}